The CONSORT Patient-Reported Outcome (PRO) extension: implications for clinical trials and practice

被引:94
作者
Calvert, Melanie [1 ]
Brundage, Michael [2 ]
Jacobsen, Paul B. [3 ]
Schuenemann, Holger J. [4 ,5 ]
Efficace, Fabio [6 ]
机构
[1] Univ Birmingham, Sch Hlth & Populat Sci, MRC Midland Hub Trials Methodol Res, Birmingham, W Midlands, England
[2] Queens Univ, Dept Med Oncol, Kingston, ON, Canada
[3] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL 33612 USA
[4] McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol, Hamilton, ON L8S 4L8, Canada
[5] McMaster Univ, Hlth Sci Ctr, Dept Biostat & Med, Hamilton, ON L8S 4L8, Canada
[6] GIMEMA Data Ctr, Italian Grp Adult Hematol Dis GIMEMA, Head Hlth Outcomes Res Unit, I-00161 Rome, Italy
来源
HEALTH AND QUALITY OF LIFE OUTCOMES | 2013年 / 11卷
基金
英国医学研究理事会; 加拿大健康研究院;
关键词
Quality of life; CONSORT PRO; Reporting; Clinical trials; QUALITY-OF-LIFE; MEDICAL JOURNALS; GUIDELINES; EDITORS; GRADE; TIME;
D O I
10.1186/1477-7525-11-184
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
To inform clinical guidelines and patient care we need high quality evidence on the relative benefits and harms of intervention. Patient reported outcome (PRO) data from clinical trials can "empower patients to make decisions based on their values" and "level the playing field between physician and patient". While clinicians have a good understanding of the concept of health-related quality of life and other PROs, evidence suggests that many do not feel comfortable in using the data from trials to inform discussions with patients and clinical practice. This may in part reflect concerns over the integrity of the data and difficulties in interpreting the results arising from poor reporting. The new CONSORT PRO extension aims to improve the reporting of PROs in trials to facilitate the use of results to inform clinical practice and health policy. While the CONSORT PRO extension is an important first step in the process, we need broader engagement with the guidance to facilitate optimal reporting and maximize use of PRO data in a clinical setting. Endorsement by journal editors, authors and peer reviewers are crucial steps. Improved design, implementation and transparent reporting of PROs in clinical trials are necessary to provide high quality evidence to inform evidence synthesis and clinical practice guidelines.
引用
收藏
页数:7
相关论文
共 25 条
  • [1] Selective reporting in clinical trials:: analysis of trial protocols accepted by The Lancet
    Al-Marzouki, Sanaa
    Roberts, Ian
    Evans, Stephen
    Marshall, Tom
    [J]. LANCET, 2008, 372 (9634) : 201 - 201
  • [2] Systems for grading the quality of evidence and the strength of recommendations -: I:: Critical appraisal of existing approaches The GRADE Working Group -: art. no. 38
    Atkins, D
    Eccles, M
    Flottorp, S
    Guyatt, GH
    Henry, D
    Hill, S
    Liberati, A
    O'Connell, D
    Oxman, AD
    Phillips, B
    Schünemann, H
    Edejer, TTT
    Vist, GE
    Williams, JW
    [J]. BMC HEALTH SERVICES RESEARCH, 2004, 4 (1)
  • [3] Quality of life in patients undergoing systemic therapy for advanced breast cancer
    Bottomley, A
    Therasse, P
    [J]. LANCET ONCOLOGY, 2002, 3 (10) : 620 - 628
  • [4] Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards
    Brundage, Michael
    Blazeby, Jane
    Revicki, Dennis
    Bass, Brenda
    de Vet, Henrica
    Duffy, Helen
    Efficace, Fabio
    King, Madeleine
    Lam, Cindy L. K.
    Moher, David
    Scott, Jane
    Sloan, Jeff
    Snyder, Claire
    Yount, Susan
    Calvert, Melanie
    [J]. QUALITY OF LIFE RESEARCH, 2013, 22 (06) : 1161 - 1175
  • [5] A knowledge translation challenge: clinical use of quality of life data from cancer clinical trials
    Brundage, Michael
    Bass, Brenda
    Jolie, Ringash
    Foley, Kimberley
    [J]. QUALITY OF LIFE RESEARCH, 2011, 20 (07) : 979 - 985
  • [6] Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers
    Brundage, Michael
    Bass, Brenda
    Davidson, Judith
    Queenan, John
    Bezjak, Andrea
    Ringash, Jolie
    Wilkinson, Anna
    Feldman-Stewart, Deb
    [J]. QUALITY OF LIFE RESEARCH, 2011, 20 (05) : 653 - 664
  • [7] Reporting of Patient-Reported Outcomes in Randomized Trials The CONSORT PRO Extension
    Calvert, Melanie
    Blazeby, Jane
    Altman, Douglas G.
    Revicki, Dennis A.
    Moher, David
    Brundage, Michael D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (08): : 814 - 822
  • [8] Chassany O, 2002, DRUG INF J, V36, P209, DOI 10.1177/009286150203600127
  • [9] Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials - Does HRQOL evaluation in prostate cancer research inform clinical decision making?
    Efficace, F
    Bottomley, A
    Osoba, D
    Gotay, C
    Flechtner, H
    D'haese, S
    Zurlo, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) : 3502 - 3511
  • [10] Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making
    Efficace, F.
    Osoba, D.
    Gotay, C.
    Sprangers, M.
    Coens, C.
    Bottomley, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (04) : 775 - 781